肖扬 特聘研究员：

1. Jingyi Hu#, Jin Ding#, Xia Li, Jun Li, Tingting Zheng, Lingxiang Xie, Chenyu Li, Yingxin Tang, Keyu Guo, Juan Huang, Shanshan Liu, Jianru Yan, Weijun Peng, Can Hou, Li Wen, Aimin Xu*, Zhiguang Zhou*, Yang Xiao*. Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study. EClinicalMedicine. 2023 Aug 3;62:102132
2. Yang Xiao#, Yanfei Wang, Jiyoon Ryu, Wei Liu, Hailan Zou, Rong Zhang, Yin Yan, Zhe Dai, Deling Zhang, Lu-Zhe Sun, Feng Liu, Zhiguang Zhou*, Lily Q Dong*. Upregulated TGF-β1 contributes to hyperglycaemia in type 2 diabetes by potentiating glucagon signalling. Diabetologia. 2023 Jun;66(6):1142-1155
3. Jingyi Hu, Rong Zhang, Hailan Zou, Lingxiang Xie, Zhiguang Zhou and Yang Xiao*.Latent Autoimmune Diabetes in Adults (LADA): From Immunopathogenesis to Immunotherapy.FRONTIERS IN ENDOCRINOLOGY.2022 Jul 21;13:917169. doi: 10.3389/fendo.2022.917169. eCollection 2022
4. Rong Zhang#,Yang Xiao#*,Jianru Yan,Wen Yang,Xiaomei WU,Zubing Mei*,Zhiguang Zhou.Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: Protocol for a Randomized Controlled Trial.FRONTIERS IN ENDOCRINOLOGY.
5. 2022 Jun 15;13:876657.doi: 10.3389/fendo.2022.876657. eCollection 2022
6. Yuqing Liu, Xin Cheng, Hongli Li , Shan Hui, Zheyu Zhang, Yang Xiao*, Weijun Peng*.Non-Coding RNAs as Novel Regulators of Neuroinflammation in Alzheimer's Disease.Frontiers in Immunology.2022 Jun 2;13:908076. doi: 10.3389/fimmu.2022.908076. eCollection 2022.PMID: 35720333 PMCID: PMC9201920

7. Huijie Yang,Weiwen Zhang,Jin Ding,Jingyi Hu,Yi Sun,Weijun Peng,Yi Chu,Lingxiang Xie,Zubing Mei,Zhuo Shao*and Yang Xiao*.

8. A novel genomic instabilityderived lncRNA signature to predict prognosis and immune characteristics of pancreaticductal adenocarcinoma. Frontiers in Immunology.2022 Sep 15;13:970588.doi: 10.3389/fimmu.2022.970588. eCollection 2022
9. Shanshan Liu,*, Chang Liu, Zhuowei Hu, and Yang Xiao*.Chemokine CCL1 as a therapeutic target for pulmonary fibrosis: comments on 'The chemokine CCL1 triggers an AMFR‒SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis'.Journal of Molecular Cell Biology.2022 Feb 24;14(1):mjab080. doi: 10.1093/jmcb/mjab080
10. Li Y, Li T*, Zhou Z, Xiao Y*. Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshot. Rev Endocr Metab Disord. 2022;23(3):569-577. doi:10.1007/s11154-021-09704-7
11. Hu JY, Zou HL, Li YH, Nie DY, Chao C, Liu JH, Ding J, Zhou ZG, Xiao Y*. Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes. Chin Med J (Engl). 2021;134(18):2243-2245. Published 2021 Sep 1. doi:10.1097/CM9.0000000000001574
12. Liu SS^#, Liu C^#, Lv XX, Cui B, Yan J, Li YX, Li K, Hua F, Zhang XW, Yu JJ, Yu JM, Wang F, Shang S, Li PP, Zhou ZG, Xiao Y*, Hu ZW*. The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis [published correction appears in Immunity. 2021 Oct 12;54(10):2433-2435]. Immunity. 2021;54(9):2042-2056.e8. doi:10.1016/j.immuni.2021.06.008
13. Li C^#, Xiao Y^#*, Hu J, et al. Associations Between Diabetes and Idiopathic Pulmonary Fibrosis: a Study-level Pooled Analysis of 26 Million People. J Clin Endocrinol Metab. 2021;106(11):3367-3380. doi:10.1210/clinem/dgab553
14. Xiao Y#, Wang H, Tang Y, et al. Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies. ESMO Open. 2021;6(4):100218. doi:10.1016/j.esmoop.2021.100218
15. Xiao Y^#, Shu L^#, Wu X, et al. Fatty acid binding protein 4 promotes autoimmune diabetes by recruitment and activation of pancreatic islet macrophages. JCI Insight. 2021;6(7):e141814. Published 2021 Apr 8. doi:10.1172/jci.insight.141814
16. Jingyi Hu#, Yingxin Tang#, Hui Liu, Yanhua Li, Xia Li, Gan Huang, Yang Xiao*, Zhiguang Zhou*.Decreased Serum Fibroblast Growth Factor 19 Level is a Risk Factor for Type 1 Diabetes.Annals of Translational Medicine. 2021 Mar;9(5):376.doi: 10.21037/atm-20-5203
17. Xing Y, Lin Q, Tong Y, Zhou W, Huang J, Wang Y, Huang G, Li Y, Xiang Z, Zhou Z, Li T, Xiao Y*. Abnormal Neutrophil Transcriptional Signature May Predict Newly Diagnosed Latent Autoimmune Diabetes in Adults of South China. Front Endocrinol (Lausanne). 2020;11:581902. Published 2020 Dec 18. doi:10.3389/fendo.2020.581902
18. Yao Yu, Qiuqiu Lin, Dewei Ye, Yanfei Wang, Binbin He, Yanhua Li, Gan Huang, Zhiguang Zhou, Yang Xiao*.Neutrophil count as a reliable marker for diabetic kidney disease in autoimmune diabetes.2020 Oct 22;20(1):158.（卷: 20 期: 1）doi: 10.1186/s12902-020-00597-2
19. Hailan Zou, Lili Liu, Jia Guo, Hongjuan Wang, Siyun Liu, Yixuan Xing, Chao Deng, Yang Xiao*.Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.JOURNAL OF DIABETES INVESTIGATION.2021 Apr;12(4):546-556. doi: 10.1111/jdi.13387. Epub 2020 Sep 19
20. Qiuqiu Lin, Wenzhi Zhou, Yanfei Wang, Juan Huang, Xiaoyan Hui, Zhiguang Zhou, Yang Xiao*.Abnormal peripheral neutrophil transcriptome in newly diagnosed type 2 diabetes patients.JOURNAL OF DIABETES RESEARCH.2020 Apr 22;2020:9519072.（卷: 2020文献号: 9519072）doi: 10.1155/2020/9519072.
21. Yue Tong, Lin Yang, Feng Shao, Xiang Yan, Xia Li, Gan Huang, Yang Xiao*, Zhiguang Zhou*.Distinct secretion pattern of serum proinsulin in different types of diabetes.ANNALS OF TRANSLATIONAL MEDICINE.2020 Apr;8(7):452.（卷: 8 期: 7；文献号: 452）doi: 10.21037/atm.2020.03.189
22. Hu J, Liu Z, Tong Y, Mei Z, Xu A, Zhou P, Chen X, Tang W, Zhou Z* , Xiao Y*. Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes. Front Endocrinol (Lausanne). 2020;11:282. Published 2020 May 22. doi:10.3389/fendo.2020.00282
23. Huang J^#, Xiao Y^#, Zheng P^#, et al. Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. Diabetes Metab Res Rev. 2019;35(1):e3064. doi:10.1002/dmrr.3064
24. Lili Liu, Zhuo Shao, Ying Xia, Jiabi Qin, Yang Xiao*, Zhiguang Zhou*, Zubing Mei.Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.ENDOCRINE CONNECTIONS.2019 Mar;8(3):277-288.（卷: 8 期: 3 页: 277-288）doi: 10.1530/EC-18-0546

25. Yang Xiao#, Xiaoyu Xiao#, Aimin Xu, Xiaoyan Chen, Weili Tang, Zhiguang Zhou*.Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes.JOURNAL OF DIABETES AND ITS COMPLICATIONS.

26. 2018 Dec;32(12):1100-1104.（卷: 32 期: 12 页: 1100-1104.DOI: 10.1016/j.jdiacomp.2018.09.001 出版年: DEC 2018文献类型:Article）
27. Yang Xiao#, Xia Li, Chen Chao, Gan Huang, Weili Tang, Shiping Liu, Zhiguo Xie, Zhiguang Zhou*.Severe Insulin Resistance Due to Insulin Antibodies.Journal of Diabetes.2018 Jul;10(7):611-613.（卷: 10 期: 7 页: 611-613.DOI: 10.1111/1753-0407.12657.出版年: JUL 2018文献类型:Letter）
28. Xiao Y^#, Liu L^#, Xu A, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:72. Published 2015 Jun 6. doi:10.1186/s12933-015-0229-9
29. Wang Y^#, Xiao Y^#, Zhong L^#, et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with β-cell autoimmunity in patients with type 1 diabetes. Diabetes. 2014;63(12):4239-4248. doi:10.2337/db14-0480
30. Xiao Y^#, Xu A, Law LS, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab. 2012;97(1):E54-E58. doi:10.1210/jc.2011-1930

刘姗姗 特聘教授：

1.      Shan-shan Liu*, Chang Liu*, Xiao-xi Lv, Bing Cui, Jun Yan, Yun-xuan Li, Ke Li, Fang Hua, Xiao-wei Zhang, Jiao-jiao Yu, Jin-mei Yu, Feng Wang, Shuang Shang, Ping-ping Li, Zhi-guang Zhou, Yang Xiao^#, and Zhuo-wei Hu^#. The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis. Immunity. 2021. 54, 2042–2056. DOI:https://doi.org/10.1016/j.immuni.2021.06.008

2.      Shan-shan Liu*, Xiao-xi Lv*, Chang Liu, Jie Qi, Yun-xuan Li, Xu-peng Wei, Ke Li, Fang Hua, Bing Cui, Xiao-wei Zhang, Jiao-jiao Yu, Jin-mei Yu, Feng Wang, Shuang Shang, Chen-xi Zhao, Xue-ying Hou, Zhi-gang Yao, Ping-ping Li, Xia Li, Bo Huang, and Zhuo-wei Hu. Targeting degradation of the transcription factor C/EBPb reduces lung fibrosis by restoring activity of the ubiquitin-editing enzyme A20 in macrophages. Immunity. 2019. 51, 522–534. DOI: 10.1016/j.immuni.2019.06.014

3.      Shan-shan Liu*, Jie Qi*, Zu-dong Teng, Fu-tao Tian, Xiao-xi Lv, Ke Li, Ya-jie Song, Wei-dong Xie, Zhuo-wei Hu^# and Xia Li^#. Resistomycin attenuates triple-negative breast cancer progression by inhibition of E3 ligase Pellino-1 activity and inducing SNAIL/SLUG degradation. Signal Transduct Target Ther. 2020, 5:133. DOI: 10.1038/s41392-020-00255-y

4.      Shan-shan Liu^#*, Xiao-xi Lv*, Xu-peng Wei, Chang Liu, Qiao Li, Jia-li Min, Fang Hua, Xiao-wei Zhang, Ke Li, Ping-ping Li, Yang Xiao, Zhuo-wei Hu, Bing Cui^#. TRIB3‒GSK-3β interaction promotes lung fibrosis and serves as a potential therapeutic target. Acta Pharm Sin B. 2021, 11(10): 3105-3119. DOI: 10.1016/j.apsb.2021.06.017

5.      Shan-shan Liu^#*, Chang Liu, Zhuo-wei Hu, Yang Xiao^#. Chemokine CCL1 as a therapeutic target for pulmonary fibrosis: comments on ‘The chemokine CCL1 triggers an AMFR–SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis’. J Mol Cell Biol. 2022, 14(1). DOI: 10.1093/jmcb/mjab080

6.      Jia-li Min, Qiao Li, Suo-si Liu, Qian-rong Wang, Min Yin, Yan Zhang, Jun Yan, Bing Cui and Shan-shan Liu. TRAF6 suppresses the development of pulmonary fibrosis by attenuating the activation of fibroblasts. Front Pharmacol. 2022, 13:911945. DOI: 10.3389/fphar.2022.911945

7.      Shan-shan Liu, Yan-feng Wang, Li-sha Ma, Bei-bei Zheng, Lin Li, Wei-dong Xie, Xia Li. 1-Oxoeudesm-11(13)-eno-12,8a-lactone induces G2/M arrest and apoptosis of human glioblastoma cells in vitro. Acta Pharmacol Sin. 2013. 34, 271-8. DOI: 10.1038/aps.2012.137

8.      Shan-shan Liu, Di Wu, Lin Li, Xiao Sun, Wei-dong Xie, Xia Li. NF-κB activation was involved in reactive oxygen species-mediated apoptosis and autophagy in 1-oxoeudesm-11(13)-eno-12,8α-lactone-treated human lung cancer cells. Arch Pharm Res. 2014. 37, 1039-52. DOI: 10.1007/s12272-013-0270-8

9.      Xiao-xi Lv*; Shan-shan Liu*; Ke Li; Bing Cui; Chang Liu; Zhuo-wei Hu. Cigarette smoke promotes COPD by activating platelet-activating factor receptor and inducing neutrophil autophagic death in mice. Oncotarget. 2017.8(43), 74720~74735. DOI: 10.18632/oncotarget.20353

10.   Xu-peng Wei, Wan-yu Wang, Yun-xuan Li, Chang Liu, Xiao-xi Lv, Yan-yan Zhao, Shan-shan Liu. [The cell cycle inhibitor p21 promote mouse lung fibrosis by activating alveolar macrophages]. Acta Pharmaceutica Sinica, 2020, 55(8): 1792-1800. (Chinese)

11.   Wan-yu Wang, Xiao-xi Lv, Zhuo-wei Hu, Shan-shan Liu. [Research progress of chemokines and their receptors in breast cancer]. Acta Pharmaceutica Sinica, 2021, 56(6): 1521-1531. (Chinese)

彭伟军 副研究员：